Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Translational Oncology Research International Genentech |
---|---|
Information provided by: | Translational Oncology Research International |
ClinicalTrials.gov Identifier: | NCT00203424 |
The purpose of this study is to evaluate the safety and effectiveness of bevacizumab plus erlotinib following radical prostatectomy.
Condition | Intervention | Phase |
---|---|---|
Prostate Cancer |
Drug: Erlotinib Drug: Bevacizumab |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer |
Estimated Enrollment: | 30 |
Study Start Date: | June 2005 |
This study explores the anti-tumor activity of adjuvant bevacizumab plus erlotinib in a select group of prostate cancer patients deemed at high risk for early relapse following radical prostatectomy.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Cancer Care Associates Medical Group, Inc. | |
Redondo Beach, California, United States, 90277 | |
Central Coast Medical Oncology Corporation | |
Santa Maria, California, United States, 93454 | |
Central Hematology Oncology Medical Group, Inc. | |
Alhambra, California, United States, 91801 | |
Comprehensive Blood and Cancer Center | |
Bakersfield, California, United States, 93309 | |
Sansum Santa Barbara Medical Foundation Clinic | |
Santa Barbara, California, United States, 93105 | |
Pacific Shores Medical Group | |
Long Beach, California, United States, 90813 | |
San Diego Cancer Center | |
Vista, California, United States, 92081 | |
North Valley Hematology/Oncology Medical Group | |
Northridge, California, United States, 91328 | |
Santa Barbara Hematology Oncology Medical Group, Inc. | |
Santa Barbara, California, United States, 93105 | |
UCLA Medical Center | |
Los Angeles, California, United States, 90095 | |
Ventura County Hematology-Oncology Specialists | |
Oxnard, California, United States, 93030 | |
Virginia K. Crosson Cancer Center | |
Fullerton, California, United States, 92835 | |
Wilshire Oncology Medical Group, Inc. | |
Pomona, California, United States, 91767 | |
United States, Florida | |
Cancer Institute of Florida, P.A. | |
Orlando, Florida, United States, 32804 | |
United States, Nevada | |
Comprehensive Cancer Centers of Nevada | |
Las Vegas, Nevada, United States, 89109 | |
United States, Texas | |
South Texas Oncology and Hematology, P.A. | |
San Antonio, Texas, United States, 78207 |
Study Chair: | Fairooz Kabbinavar, MD | Chief Medical Officer, TORI |
Study ID Numbers: | TORI GU-01 |
Study First Received: | September 13, 2005 |
Last Updated: | July 30, 2009 |
ClinicalTrials.gov Identifier: | NCT00203424 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Erlotinib Prostatic Diseases Genital Neoplasms, Male Adjuvants, Immunologic Urogenital Neoplasms |
Bevacizumab Genital Diseases, Male Protein Kinase Inhibitors Angiogenesis Inhibitors Prostatic Neoplasms |
Erlotinib Molecular Mechanisms of Pharmacological Action Genital Neoplasms, Male Prostatic Diseases Antineoplastic Agents Growth Substances Physiological Effects of Drugs Enzyme Inhibitors Urogenital Neoplasms Bevacizumab |
Genital Diseases, Male Protein Kinase Inhibitors Angiogenesis Inhibitors Pharmacologic Actions Neoplasms Neoplasms by Site Therapeutic Uses Growth Inhibitors Angiogenesis Modulating Agents Prostatic Neoplasms |